TIMELESS: Late-Window Tenecteplase Fails to Improve Stroke Outcomes
This trial informs neurology pharmacists whether adding intravenous tenecteplase to standard care (mostly thrombectomy) benefits perfusion-selected patients presenting 4.5 to 24 hours after stroke onset.
📅 Journal publication: Feb 22, 2024(online Feb 8, 2024)·Last updated: Jul 18, 2026
Tenecteplase fails to outperform placebo in delayed stroke treatment.
Exploring tenecteplase for ischemic stroke beyond 4.5 hours could expand treatment options for patients presenting late. Tenecteplase did not improve outcomes compared to placebo when administered 4.5 to 24 hours after stroke onset, with similar mortality and hemorrhage rates. The study showed no clinical benefit of late tenecteplase administration; further research needed for alternative late treatment strategies. Tenecteplase beyond 4.5 hours offers no added benefit in stroke outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, Sangha N, Kim M, Froehler MT, Schwartz NE, Clark WM, Kircher CE, Yang M, Massaro L, Lu XY, Rippon GA, Broderick JP, Butcher K, Lansberg MG, Liebeskind DS, Nouh A, Schwamm LH, Campbell BCV, TIMELESS Investigators
Citation:Albers GW, Jumaa M, Purdon B, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. The New England journal of medicine. 2024;390(8):701-711. doi:10.1056/NEJMoa2310392